Novo Nordisk


Strong Q1 prompts an improved guidance

05/05/21 -"2021 started on a high as Novo reported robust growth, despite ‘tough comps’, i.e. forward buying-driven Q1 20. Moreover, as management expects this momentum to be maintained, the 2021 outlook has ..."

Pages
72
Language
English
Published on
05/05/21
You may also be interested by these reports :
22/10/26
The Q3 sales were ahead of the street’s expectations, driven by healthy growth across both segments. The beat, though, received support from a ...

22/10/26
Ipsen reported a robust Q3, resulting in an upgraded 2026 guidance. While we may revise our estimates upwards, we do not anticipate a significant ...

22/10/26
A guidance upgrade on top of the modest outlook uplift in July 2026 reflects UCB’s habit of making modest promises and then over-delivering. ...

20/10/26
The Q3 sales growth surpassed the full-year guidance range, backed by healthy growth in companion and farm animal segments across geographies. The ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO